Gabri Labs to invest Dhs18m in new manufacturing facility in Dubai Science Park

Gabri Labs, a pharmaceutical technologies company, will open a facility in Dubai Science Park to locally produce medical devices.

Gabri Lab’s new facility will allow it to produce an initial volume of 12 million units per year, with further expansions planned by 2023.

The 10,000 sq ft facility will be built with an investment of Dhs18m and will support the production of multiple lines and a diverse product portfolio including ENT brand, OTOMAR, and dermatological solutions line, Curadem.

The medical devices will have the ‘Make it in the Emirates’ stamp – a government-backed initiative to boost the local manufacturing industry – and will be distributed to markets across the MENA region.

Gabri Labs Labs is a privately held pharmaceutical company headquartered in Dover, Delaware, with production facilities spread across Europe and the Middle East. It is most widely known for its production of devices and over-the-counter products that address the requirements of the therapeutic areas of ENT and dermatology.

The UAE’s medical device market, according to American credit rating agency Fitch Solutions, is expected to reach Dhs5.6bn by 2025.

“Pharmaceutical companies are increasingly choosing our emirate as a destination to expand operations into the MENA region, backed by an enabling business environment and regulatory framework. Dubai Science Park strives to facilitate the expansion of international firms like Gabri Labs by continually providing them access to robust infrastructure, communication with key regulatory bodies and a collaborative ecosystem that eases business set-up and growth,” said Marwan Abdulaziz Janahi, managing director of Dubai Science Park.

Elio Gebrayel, managing director of Gabri Labs, added, “Dubai Science Park’s dynamic business environment and robust infrastructure have been essential in facilitating our seamless setup, allowing us to easily access MENA’s diverse markets while participating in a vibrant community of researchers, scientists, pharmacists and more. Our new facility will allow us to cater to more patients across the region and continue innovating and leading the therapeutic ENT and dermatology sectors.”

Last year, Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of UAE and Ruler of Dubai, launched the Industrial Strategy Operation 300bn. The 10-year comprehensive strategy aims to expand increase the contribution of the industrial sector to the country’s GDP from the Dhs133bn to Dhs300bn by 2031.

Read: Sheikh Mohammed launches ‘Operation 300bn’ strategy to foster UAE industrial sector